Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects

D P Dearnaley, E Hall, D Lawrence, R A Huddart, R Eeles, C M Nutting, J Gadd, A Warrington, M Bidmead, A Horwich, D P Dearnaley, E Hall, D Lawrence, R A Huddart, R Eeles, C M Nutting, J Gadd, A Warrington, M Bidmead, A Horwich

Abstract

Radical radiotherapy is a standard form of management of localised prostate cancer. Conformal treatment planning spares adjacent normal tissues reducing treatment-related side effects and may permit safe dose escalation. We have tested the effects on tumour control and side effects of escalating radiotherapy dose and investigated the appropriate target volume margin. After an initial 3-6 month period of androgen suppression, 126 men were randomised and treated with radiotherapy using a 2 by 2 factorial trial design. The initial radiotherapy tumour target volume included the prostate and base of seminal vesicles (SV) or complete SV depending on SV involvement risk. Treatments were randomised to deliver a dose of 64 Gy with either a 1.0 or 1.5 cm margin around the tumour volume (1.0 and 1.5 cm margin groups) and also to treat either with or without a 10 Gy boost to the prostate alone with no additional margin (64 and 74 Gy groups). Tumour control was monitored by prostate-specific antigen (PSA) testing and clinical examination with additional tests as appropriate. Acute and late side effects of treatment were measured using the Radiation Treatment and Oncology Groups (RTOG) and LENT SOM systems. The results showed that freedom from PSA failure was higher in the 74 Gy group compared to the 64 Gy group, but this did not reach conventional levels of statistical significance with 5-year actuarial control rates of 71% (95% CI 58-81%) in the 74 Gy group vs 59% (95% CI 45-70%) in the 64 Gy group. There were 23 failures in the 74 Gy group and 33 in the 64 Gy group (Hazard ratio 0.64, 95% CI 0.38-1.10, P=0.10). No difference in disease control was seen between the 1.0 and 1.5 cm margin groups (5-year actuarial control rates 67%, 95% CI 53-77% vs 63%, 95% CI 50-74%) with 28 events in each group (Hazard ratio 0.97, 95% CI 0.50-1.86, P=0.94). Acute side effects were generally mild and 18 weeks after treatment, only four and five of the 126 men had persistent > or =Grade 1 bowel or bladder side effects, respectively. Statistically significant increases in acute bladder side effects were seen after treatment in the men receiving 74 Gy (P=0.006), and increases in both acute bowel side effects during treatment (P=0.05) and acute bladder sequelae (P=0.002) were recorded for men in the 1.5 cm margin group. While statistically significant, these differences were of short duration and of doubtful clinical importance. Late bowel side effects (RTOG> or =2) were seen more commonly in the 74 Gy and 1.5 cm margin groups (P=0.02 and P=0.05, respectively) in the first 2 years after randomisation. Similar results were found using the LENT SOM assessments. No significant differences in late bladder side effects were seen between the randomised groups using the RTOG scoring system. Using the LENT SOM instrument, a higher proportion of men treated in the 74 Gy group had Grade > or =3 urinary frequency at 6 and 12 months. Compared to baseline scores, bladder symptoms improved after 6 months or more follow-up in all groups. Sexual function deteriorated after treatment with the number of men reporting some sexual dysfunction (Grade> or =1) increasing from 38% at baseline to 66% at 6 months and 1 year and 81% by year 5. However, no consistent differences were seen between the randomised groups. In conclusion, dose escalation from 64 to 74 Gy using conformal radiotherapy may improve long-term PSA control, but a treatment margin of 1.5 cm is unnecessary and is associated with increased acute bowel and bladder reactions and more late rectal side effects. Data from this randomised pilot study informed the Data Monitoring Committee of the Medical Research Council RT 01 Trial and the two studies will be combined in subsequent meta-analysis.

Figures

Figure 1
Figure 1
Consort diagram.
Figure 2
Figure 2
(A) Time to PSA failure: 74 vs 64 Gy dose randomization; (B) Time to PSA failure: 1.5 vs 1.0 cm margin randomization.
Figure 3
Figure 3
Acute bowel and bladder toxicities by dose and margin randomization. (A) Acute bowel toxicity (RTOG) by dose randomization; (B) Acute bladder toxicity (RTOG) by dose randomization; (C) Acute bowel toxicity (RTOG) by margin randomization; (D) Acute bladder toxicity (RTOG) by margin randomization.
Figure 4
Figure 4
Cumulative grade ⩾2 bowel and bladder toxicities by dose and margin randomization. (A) Cumulative bowel toxicity grade ⩾2 by dose; (B) cumulative bladder toxicity grade ⩾2 by dose; (C) cumulative bowel toxicity grade ⩾2 by margin; (D) cumulative bladder toxicity grade ⩾2 by margin.

References

    1. Amer AM, Mackay RI, Roberts SA, Hendry JH, Williams PC (2001) The required number of treatment imaging days for an effective off-line correction of systematic errors in conformal radiotherapy of prostate cancer – a radiobiological analysis. Radiother Oncol 61: 143–150
    1. Anacak Y, Yalman D, Ozsaran Z, Haydaroglu A (2001) Late radiation effects to the rectum and bladder in gynecologic cancer patients: the comparison of LENT/SOMA and RTOG/EORTC late-effects scoring systems. Int J Radiat Oncol Biol Phys 50: 1107–1112
    1. Bey P, Carrie C, Beckendorf V, Ginestet C, Aletti P, Madelis G, Luporsi E, Pommier P, Cowen D, Gonzague-Casabianca L, Simonian-Sauve M, Maingon P, Naudy S, Lagrange J, Marcie S (2000) Dose escalation with 3D-CRT in prostate cancer: French study of dose escalation with conformal 3D radiotherapy in prostate cancer-preliminary results. Int J Radiat Oncol Biol Phys 48: 513–517
    1. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV (1998) Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 Gy) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41: 83–92, issn: 0360–3016
    1. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M (2002) Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 360: 103–106
    1. Brenner DJ (2000) Toward optimal external-beam fractionation for prostate cancer. Int J Radiat Oncol Biol Phys 48: 315–316
    1. COIN Guidelines (1999) COIN Guidelines for the Management of Prostate Cancer. Clin Oncol (R Coll Radiol) 11: 135–172
    1. Consensus conference (1987) The management of clinically localized prostate cancer. JAMA 258: 2727–2730
    1. Cox JD, Stetz J, Pajak TF (1995) Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys 31: 1341–1346
    1. Crook JM, Raymond Y, Salhani D, Yang H, Esche B (1995) Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37: 35–42
    1. D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP (2002) Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 54: 436–441
    1. Dearnaley DP (2000) Combined modality treatment with radiotherapy and hormonal treatment in localized prostate cancer. In New Perspectives in Prostate Cancer. Belldegrun A, Kirby RS, Newling DWW (eds) pp. 169–180. Oxford: Isis Medical Media Ltd
    1. Dearnaley DP (2001) Radiotherapy and combined modality approaches in localised prostate cancer. Eur J Cancer 37: S137–S145
    1. Dearnaley DP, Khoo VS, Norman A, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353: 267–272
    1. Denham JW, O'Brien PC, Dunstan RH, Johansen J, See A, Hamilton CS, Bydder S, Wright S (1999) Is there more than one late radiation proctitis syndrome? Radiother Oncol 51: 43–53
    1. Duchesne GM, Peters LJ (1999) What is the alpha/beta ratio for prostate cancer? Rationale for hypofractionated high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 44: 747–748
    1. Fenwick JD, Khoo VS, Nahum AE, Sanchez-Nieto B, Dearnaley DP (2001) Correlations between dose–surface histograms and the incidence of long-term rectal bleeding following conformal or conventional radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys 49: 473–480
    1. Fiorino C, Sanguineti G, Vavassori V, Bianchi C, Foppiano F, Magli A, Piazzolla A, Cattaneo GM (2003) Correlation between dose–volume constraints and late rectum bleeding in patients treated for prostate cancer at dose between 70 and 76 Gy. In ASTRO. San Francisco, California
    1. Fiveash JB, Hanks G, Roach M, Wang S, Vigneault E, McLaughlin PW, Sandler HM (2000) 3D conformal radiation therapy (3DCRT) for high grade prostate cancer: a multi-institutional review. Int J Radiat Oncol Biol Phys 47: 335–342
    1. Forman JD, Kumar R, Haas G, Montie J, Porter AT, Mesina CF (1995) Neoadjuvant hormonal downsizing of localized carcinoma of the prostate: effects on the volume of normal tissue irradiation. Cancer Invest 13: 8–15
    1. Fuks Z, Horwich A (1993) Clinical and technical aspects of conformal therapy. Radiother Oncol 29: 219–220
    1. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MA (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization, and future directions. Int J Radiat Oncol Biol Phys 41: 501–510
    1. Horwitz EM, Winter K, Hanks GE, Lawton CA, Russell AH, Machtay M (2001) Subset analysis of RTOG 85-31 and 86-10 indicates an advantage for long-term vs short-term adjuvant hormones for patients with locally advanced nonmetastatic prostate cancer treated with radiation therapy. Int J Radiat Oncol Biol Phys 49: 947–956
    1. ICRU (1993) Prescribing, Recording and Reporting Photon Beam Therapy. Bethesda, MD: International Commission for Radiation Units and Measurements
    1. Jackson A, Skwarchuk MW, Zelefsky MJ, Cowen DM, Venkatraman ES, Levegrun S, Burman CM, Kutcher GJ, Fuks Z, Liebel SA, Ling CC (2001) Late rectal bleeding after conformal radiotherapy of prostate cancer. II. Volume effects and dose–volume histograms. Int J Radiat Oncol Biol Phys 49: 685–698
    1. Khoo VS, Bedford JL, Webb S, Dearnaley DP (2000) An evaluation of three-field coplanar plans for conformal radiotherapy of prostate cancer. Radiother Oncol 55: 31–40
    1. King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51: 213–214
    1. Kupelian PA, Mohan DS, Lyons J, Klein EA, Reddy CA (2000) Higher than standard radiation doses (> or =72 Gy) with or without androgen deprivation in the treatment of localized prostate cancer. Int J Radiat Oncol Biol Phys 46: 567–574
    1. Laverdiere J, Gomez JL, Cusan ER, Suburu ER, Diamond P, Lemay M, Candas B, Fortin A, Labrie F (1997) Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localised prostate cancer. Int J Radiat Oncol Biol Phys 37: 247–252
    1. Laverdiere J, Nabid A, De Bedoya LD, Ebacher A, Fortin A, Wang CS, Harel F (2004) The efficacy and sequencing of a short course of androgen suppression on freedom from biochemical failure when administered with radiation therapy for T2-T3 prostate cancer. J Urol 171: 1137–1140
    1. Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, Cox JD, Perez CA, Sause WT, Doggett SRL, Rubin P (1991) Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 21: 935–939
    1. Lee WR, Hanks GE, Hanlon AL, Schultheiss TE, Hunt MA (1996) Lateral rectal shielding reduced late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localised prostate cancer: Further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 35: 251–257
    1. Lu Y, Song PY, Li SD, Spelbring DR, Vijayakumar S, Haraf DJ, Chen GT (1995) A method of analyzing rectal surface area irradiated and rectal complications in prostate conformal radiotherapy. Int J Radiat Oncol Biol Phys 33: 1121–1125
    1. Michalski JM, Purdy JA, Winter K, Roach III M, Vijayakumar S, Sandler HM, Markoe AM, Ritter MA, Russell KJ, Sailer S, Harms WB, Perez CA, Wilder RB, Hanks GE, Cox JD (2000) Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 46: 391–402
    1. Mubata CD, Bidmead AM, Ellingham LM, Thompson LM, Dearnaley DP (1998) Portal imaging protocol for radical dose-escalated radiotherapy treatment of prostate cancer. Int J Radiat Oncol Biol Phys 40: 221–231
    1. Murphy GP, Busch C, Abrahamsson PA, Epstein JI, McNeal JE, Miller GJ, Mostofi FK, Nagle RB, Nordling S, Parkinson C (1994) Histopathology of localized prostate cancer. Consensus Conference on Diagnosis and Prognostic Parameters in Localized Prostate Cancer. Stockholm, Sweden, May 12–13, 1993. Scand J Urol Nephrol Suppl 162: 7–42; discussion 115–127
    1. Nutting C, Khoo V, Walker V, McNair H, Beardmore C, Norman A, Dearnaley D (2000) A randomised study of the use of a customised immobilisation system in the treatment of prostate cancer with conformal radiotherapy. Radiother Oncol 54: 1–9
    1. Padhani AR, Khoo VS, Sucking J, Husband JE, Leach MO, Dearnaley DP (1999) Evaluating the effect of rectal distension and rectal movement on prostate gland position using cine MRI. Int J Radiat Biol Phys 44: 525–533
    1. Parker C, Norman AR, Huddart RA, Horwich A, Dearnaley DP (2002) Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer. Br J Cancer 86: 686–691
    1. Pickett B, Roach M, Horine P, Verhey L, Phillips TL (1994) Optimization of the oblique angles in the treatment of prostate cancer during six-field conformal radiotherapy. Med Dosimetry 19: 237–254
    1. Pilepich MV, Winter K, John MJ, Mesic JB, Sause W, Rubin P, Lawton C, Machtay M, Grignon D (2001) Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiat Oncol Biol Phys 50: 1243–1252
    1. Pilepich MV, Winter K, Lawton C, Krisch RE, Wolkov H, Movsas B, Hug E, Asbell S, Grignon D (2003) Androgen suppression adjuvant to radiotherapy in carcinoma of the prostate. long-term results of phase III RTOG study 85-31. Int J Radiat Oncol Biol Phys 57: S172–S173
    1. Pollack A, Zagars GK, Smith LG, Lee JJ, von Eschenbach AC, Antolak JA, Starkschall G, Rosen I (2000) Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18: 3904–3911
    1. Porter AT, Ethliali M, Manji M (1998) A phase III randomised trial to evaluate the efficacy of neoadjuvant therapy prior to curative radiotherapy in locally advanced prostate cancer patients. A Canadian Urologic Oncology Group Study. Proc Am Soc Clin Oncol 17, Abstract 1123
    1. Roach III M (1993) Re: the use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150: 1923–1924
    1. Roach III M, Lu J, Pilepich MV, Asbell SO, Mohiuddin M, Terry R, Grignon D, Lawton C, Shipley W, Cox J, Mohuidden M (2000) Predicting long-term survival, and the need for hormonal therapy: a meta-analysis of RTOG prostate cancer trials. Int J Radiat Oncol Biol Phys 47: 617–627
    1. RTOG/EORTC LENT SOM (1995) LENT SOMA tables. Radiother Oncol 35: 17–60
    1. Sandler HM, Perez-Tomayo C, Ten Haken RK, Lichter AS (1992) Dose escalation for stage C (T3) prostate cancer: minimal rectal toxicity observed using conformal therapy. Radiother Oncol 23: 53–54
    1. Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE (1997) Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 37: 3–11
    1. Seddon B, Bidmead M, Wilson J, Khoo V, Dearnaley D (2000) Target volume definition in conformal radiotherapy for prostate cancer: quality assurance in the MRC RT-01 trial. Radiother Oncol 56: 73–83
    1. Shahidi M, Norman AR, Gadd J, Huddart RA, Horwich A, Dearnaley DP (2001) Recovery of serum testosterone, LH and FSH levels following neoadjuvant hormone cytoreduction and radical radiotherapy in localised prostate cancer. Clin Oncol 13: 291–295
    1. Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD (1999) Radiation therapy for clinically localised prostate cancer: a multi-institutional pooled analysis. JAMA 281: 1598–1604
    1. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, Burman CM, Fuks Z, Leibel SA, Ling CC (2000) Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose–response. Int J Radiat Oncol Biol Phys 47: 103–113
    1. Sydes MR, Stephens RJ, Moore AR, Aird EG, Bidmead AM, Fallowfield LJ, Graham J, Griffiths S, Mayles WP, McGuire A, Stanley S, Warrington AP, The RT01 Collaborators, Dearnaley DP (2004) Implementing the UK Medical Research Council (MRC) RT01 trial (ISRCTN 47772397): methods and practicalities of a randomised controlled trial of conformal radiotherapy in men with localised prostate cancer. Radiother Oncol 72: 199–211
    1. Tinger A, Michalski JM, Cheng A, Low DA, Zhu R, Bosch WR, Purdy JA, Perez CA (1998) A critical evaluation of the planning target volume for 3-D conformal radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 42: 213–221, issn: 0360–3016
    1. UICC (1997) TNM Classification of Malignant Tumours. International Union Against Cancer. Geneva: Springer-Verlag
    1. Valicenti R, Lu J, Pilepich M, Asbell S, Grignon D (2000) Survival advantage from higher-dose radiation therapy for clinically localized prostate cancer treated on the Radiation Therapy Oncology Group trials. J Clin Oncol 18: 2740–2746
    1. Wachter S, Gerstner N, Goldner G, Potzi R, Wambersie A, Potter R (2001) Rectal sequelae after conformal radiotherapy of prostate cancer: dose–volume histograms as predictive factors. Radiother Oncol 59: 65–70
    1. Wu J, Haycocks T, Alasti H, Ottewell G, Middlemiss N, Abdolell M, Warde P, Toi A, Catton C (2001) Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 61: 127–133
    1. Zelefsky MJ, Cowen D, Fuks Z, Shike M, Burman C, Jackson A, Venkatramen ES, Leibel SA (1999) Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma. Cancer 85: 2460–2468
    1. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166: 876–881
    1. Zelefsky MJ, Leibel SA, Burman CM, Kutcher GJ, Harrison A, Happersett L, Fuks Z (1994) Neoadjuvant hormonal therapy improves the therapeutic ratio in patients with bulky prostatic cancer treated with three-dimensional conformal radiation therapy. Int J Radiat Oncol Biol Phys 29(4): 755–761
    1. Zelefsky MJ, Leibel SA, Gaudin PB, Kutcher GJ, Fleshner NE, Venkatramen ES, Reuter VE, Fair WR, Ling CC, Fuks Z (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41: 491–500

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera